blood cancer
ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development
July 29, 2025Contract Manufacturing, Manufacturing Services, Mergers and Acquisitions, Research and Development AvenCell Therapeutics, CAR-T therapy, Contract Development Manufacturing Organisation, Good Manufacturing Practice, Immunology, Oncology, ViroCell Biologics, autoimmune diseases, blood cancer
ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield retroviral vector supporting the clinical …
Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
June 24, 2025Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …
New CAR T Vision Coalition and roadmap report to launch at ASCO aims to double patients treated with CAR T-cell therapy by 2030
June 3, 2025Research and Development American Society of Clinical Oncology, CAR T Vision, CAR T-cell therapy, International Myeloma Foundation, Kite, Leukemia & Lymphoma Society, Oncology, blood cancer
For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, healthier life, and for some, …
Innate Pharma shares results from phase 1/2 trial for blood cancer treatment
June 17, 2024Research and Development Innate Pharma, Oncology, blood cancer, clinical trial
Innate Pharma has announced updated efficacy and safety results from the dose-escalation part of the phase 1/2 study with SAR443579/IPH6101 …
Regeneron plans to share advancements from blood cancer pipeline
November 6, 2023Medical Communications ASH annual meeting, Haematology, Regeneron, blood cancer, haematology
Regeneron Pharmaceuticals have announced that it plans to share new and updated data from its haematology pipeline at the American …
Antion launch new technology for cancer and tumour treatments
March 18, 2021Cancer, action, blood cancer, myeloma
Antion Biosciences has launched a new T-cell technology platform to help with the development of new curative therapies for diseases …
ONK and Anthony Nolan combine forces to work on blood cancer therapies
February 22, 2021Sales and Marketing Anthony Nolan, Cancer, ONK, blood cancer, cancer treatment
ONK Therapeutics and blood cancer charity Anthony Nolan will work together on therapies for patients with haematological malignancies (blood cancers) …
Researchers find Achilles’ heel protein in leukaemia
April 26, 2019Medical Communications AML, Edinburgh, Protein, YTHDF2, blood cancer, drug targets, leukaemia
An international team of researchers have identified an “Achilles’ heel” protein that could lead to the development of novel treatments …
Novartis’ Kymriah & Gilead’s Yescarta become first EU-approved CAR T therapies
August 28, 2018Manufacturing and Production, Sales and Marketing CAR T, CAR-T, Cancer, EU, Gilead, Kymriah, Novartis, UK, Yescarta, blood cancer, pharma
Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …
Blood cancer patients over 75 are significantly underrepresented in clinical trials, study finds
December 13, 2017Research and Development FDA, blood cancer, leukaemia, lymphoma, myeloid leukaemia, pharma
The FDA’s first comprehensive analysis of clinical trial enrolment in older patients with blood cancers has revealed that the population …
FDA expands Roche drug indication to approve first-ever treatment for rare blood cancer
November 7, 2017Manufacturing and Production, Sales and Marketing Cancer, Erdheim-Chester Disease, FDA, Roche, blood cancer, pharma
The FDA has announced the approval of Roche’s Zelboraf (vemurafenib) in the treatment of Erdheim-Chester Disease (ECD), expanding its already …
Existing arthritis drug could save thousands in blood cancer treatment
August 3, 2017Research and Development University of Sheffield, arthritis, biotech, blood cancer, drugs, life sciences, medicine, pharma, pharmaceutical
Findings by researchers at the University of Sheffield have indicated that thousands of pounds could be saved in blood cancer …
Bayer celebrates FDA priority review for investigational blood cancer drug
May 17, 2017Research and Development, Sales and Marketing Bayer, FDA, blood cancer
Bayer has announced that its investigational blood cancer treatment copanlisib has been awarded priority review designation from the FDA, meaning …
Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund
July 7, 2016Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif
The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …
Amgen says its blood cancer drug gets European backing for extended indication
July 4, 2016Research and Development, Sales and Marketing Amgen, European Commission, Kyprolis, blood cancer, drug trial
Amgen (Nasdaq: AMGN) said the European Commission (EC) has approved a variation to the marketing authorization for its Kyprolis (carfilzomib) to include use …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
